Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATON NASDAQ:BCLI NYSE:NKGN NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.33$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsBCLIBrainstorm Cell Therapeutics$0.68$0.80$0.46▼$1.33$7.51M0.2216,586 shs1,817 shsNKGNNKGen Biotech$0.06$0.07$0.00▼$0.46$7.84M0.664,755 shs50,527 shsSBFMSunshine Biopharma$0.48$0.93$0.28▼$2.43$2.41M1.3738.90 million shs16.33 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%0.00%-17.00%+33,199,900.00%BCLIBrainstorm Cell Therapeutics0.00%-1.43%-11.68%+7.95%-37.03%NKGNNKGen Biotech0.00%0.00%0.00%0.00%-79.30%SBFMSunshine Biopharma0.00%-5.63%-51.87%-58.86%-66.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.33$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsBCLIBrainstorm Cell Therapeutics$0.68$0.80$0.46▼$1.33$7.51M0.2216,586 shs1,817 shsNKGNNKGen Biotech$0.06$0.07$0.00▼$0.46$7.84M0.664,755 shs50,527 shsSBFMSunshine Biopharma$0.48$0.93$0.28▼$2.43$2.41M1.3738.90 million shs16.33 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%0.00%-17.00%+33,199,900.00%BCLIBrainstorm Cell Therapeutics0.00%-1.43%-11.68%+7.95%-37.03%NKGNNKGen Biotech0.00%0.00%0.00%0.00%-79.30%SBFMSunshine Biopharma0.00%-5.63%-51.87%-58.86%-66.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATONPortage Biotech 2.00Hold$2.00502.41% UpsideBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ASBFMSunshine Biopharma 2.00Hold$7.001,354.39% UpsideCurrent Analyst Ratings BreakdownLatest SBFM, BCLI, NKGN, and ATON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SBFMSunshine Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATONPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/ASBFMSunshine Biopharma$36.31M0.07N/AN/A$4.30 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATONPortage Biotech-$6.77M-$8.18N/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics-$11.62M-$1.64N/AN/AN/AN/AN/A-519.50%N/ANKGNNKGen Biotech-$82.94M-$1.51N/AN/AN/AN/AN/A-479.36%N/ASBFMSunshine Biopharma-$5.97M-$1.29N/AN/AN/A-18.45%-27.75%-21.57%8/5/2026 (Estimated)Latest SBFM, BCLI, NKGN, and ATON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SBFMSunshine Biopharma-$0.16-$0.25-$0.09-$0.25$9.20 million$8.09 million4/3/2026Q4 2025SBFMSunshine Biopharma-$0.27-$0.46-$0.19-$0.46$10.00 million$8.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATONPortage BiotechN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATONPortage BiotechN/A0.880.88BCLIBrainstorm Cell TherapeuticsN/A0.210.21NKGNNKGen BiotechN/A0.020.02SBFMSunshine BiopharmaN/A4.221.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATONPortage Biotech13.36%BCLIBrainstorm Cell Therapeutics14.33%NKGNNKGen Biotech76.17%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipATONPortage BiotechN/ABCLIBrainstorm Cell Therapeutics11.15%NKGNNKGen Biotech10.36%SBFMSunshine Biopharma0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATONPortage Biotech623.44 millionN/AN/ABCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableNKGNNKGen BiotechN/A130.60 million40.29 millionNot OptionableSBFMSunshine Biopharma35.01 million5.00 millionNot OptionableSBFM, BCLI, NKGN, and ATON HeadlinesRecent News About These CompaniesSunshine Biopharma Receives Canadian Regulatory Approval for Generic AmoxicillinMay 21, 2026 | accessnewswire.comASunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public OfferingMay 19, 2026 | accessnewswire.comASunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingMay 18, 2026 | accessnewswire.comASBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearApril 6, 2026 | accessnewswire.comASunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)October 28, 2025 | accessnewswire.comASunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 21, 2025 | finanznachrichten.deSunshine Biopharma announces commercial launch of doxycycline in CanadaOctober 20, 2025 | msn.comSunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 20, 2025 | accessnewswire.comASunshine Biopharma stock soars after launch of cholesterol drug PravastatinOctober 16, 2025 | au.investing.comSunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian UnitOctober 16, 2025 | msn.comSunshine Biopharma Launches Cholesterol Fighting Medicine PravastatinOctober 16, 2025 | accessnewswire.comASunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level ExecutionOctober 14, 2025 | finanznachrichten.deSunshine Biopharma allocates $5M for investment in bitcoinOctober 14, 2025 | msn.comSunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)October 14, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBFM, BCLI, NKGN, and ATON Company DescriptionsPortage Biotech NASDAQ:ATON$0.33 +0.01 (+3.75%) Closing price 04/20/2026Extended Trading$0.33 0.00 (0.00%) As of 04/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.Brainstorm Cell Therapeutics NASDAQ:BCLI$0.68 0.00 (0.00%) As of 05/22/2026 03:25 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.NKGen Biotech NYSE:NKGN$0.06 0.00 (0.00%) As of 05/22/2026 03:44 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Sunshine Biopharma NASDAQ:SBFM$0.48 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.46 -0.02 (-3.59%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
